Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287248 · ClinicalTrials.gov registry record · Phase 1
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain
A Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT00287248 is a Phase 1 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 38 participants.
The verdict
NCT00287248, a Phase 1 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This research is designed to obtain efficacy and safety information for 123-I IMPY as an imaging biomarker for Alzheimer's disease (AD). The distribution of this agent will be measured by obtaining single photon emission computed tomography (SPECT) images of the brain serially over time to determine the relative localization of the radiopharmaceutical in regions of the cortex relative to background regions and develop an optimal technique of radiotracer administration (bolus or bolus with constant infusion). The researchers will then evaluate the utility of 123-I IMPY and SPECT in AD patients as an early diagnostic tool and subsequently serial evaluations of AD patients will be performed to determine if this technique may be useful as a tool for evaluation of progressive brain β-amyloid deposition in AD.
Interventions
- DRUG [123I] IMPY & SPECT Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00287248
The ClinicalTrials.gov registry entry for NCT00287248 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [123I] IMPY & SPECT Imaging is the first listed.
NCT00287248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00287248 about?
NCT00287248 is a clinical study titled "Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain". This research is designed to obtain efficacy and safety information for 123-I IMPY as an imaging biomarker for Alzheimer's disease (AD). The distribution of this agent will be measured by obtaining single photon emission computed tomography (SPECT) images of the brain serially over time to determine...
What is the current status of trial NCT00287248?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2006-02. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00287248?
The interventions under investigation include: [123I] IMPY & SPECT Imaging (DRUG).
Who is sponsoring clinical trial NCT00287248?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.